The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

US-based genomic therapy developer Beam Therapeutics, whose investors include internet and technology conglomerate Alphabet, closed its initial public offering at $207m yesterday. The company priced 10.6 million shares at the top of a $15 to $17 range to raise $180m last week having already increased the number of shares it was offering. The shares closed…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.